Efficacy of Tocilizumab in COVID-19: Single-Center Experience
Table 2
Comparison of laboratory findings of the patients with COVID-19 infection at hospital admission and tocilizumab administration day in the mortality group (Group 1) and survival group (Group 2).
Variables
Overall ()
Group 1 ()
Group 2 ()
value
At hospital admission
SpO2 (%)
88 (83-91)
84.5 (80-90)
88.5 (85-92)
<0.001
Temperature (°C)
37.2 (36.8-37.8)
37.4 (36.9-38)
37 (36.77-37.52)
0.005
Lymphocytes (×103/mL)
0.9 (0.6-1.2)
0.8 (0.6-0.9)
1 (0.6-1.4)
<0.001
CRP (mg/L)
105 (62-154.5)
139 (55-182)
105.5 (58.7-151.7)
0.021
Ferritin (μg/dL)
759.5 (455.5- 1295)
779 (393-1380)
693.5 (401-1058.2)
0.964
d-dimer (ng/mL)
308 (192.5-472.5)
400 (264-837)
260.5 (173.7-386.5)
0.001
ALT (U/L)
31.5 (22-53.5)
26 (17-33)
27 (20-49.2)
0.036
AST (U/L)
39 (28.5-58)
37 (26-49)
35 (25.7-59.5)
0.675
At the first dose of TCZ
SpO2 (%)
84 (79-88)
80 (75-84)
84 (81-86)
<0.001
Temperature (°C)
37.9 (37.6-38.2)
37.85 (37.5-38.1)
37.8 (37.6-38.1)
0.073
Lymphocytes (×109/L)
0.7 (0.5-1)
0.5 (0.4-0.9)
0.7 (0.5-1)
<0.001
CRP (mg/dL)
152 (11-210)
169 (123-250)
135.5 (121-184.2)
<0.001
Ferritin (mg/dL)
1330.5 (789.5-2000)
1275 (842-1800)
1145 (767.5-1635.7)
0.496
d-dimer (ng/dL)
734.5 (359.5-2191)
988.5 (542-2772)
776.5 (350.7-2169.7)
<0.001
ALT (U/L)
41.0 (24-65)
35.0 (23-65)
41 (23.0-58.2)
0.005
AST (U/L)
41.5 (29-65)
55.5 (37-80)
36.5 (24.7-60.7)
0.156
Statistically significant. The categorical data are expressed as (%), and the continuous data are expressed as median (interquartile range (IQR): 25th, 75th percentile). HA: hospital admission; TCZ: tocilizumab; SpO2: oxygen saturation measured by pulse oximetry; CRP: C-reactive protein; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
